New treatment decisions for lung cancer
April 14, 2010
httpv://www.youtube.com/watch?v=nIjFWKIbGy0
Over the last ten years, new drugs and genetic tests have developed for the treatment of non-small cell lung cancer (NSCLC). EGFR antibodies (Erbitux by Eli Lilly, Vectibix by Amgen), and small molecule oral pills targeting the tyrosine kinase pathway (Tarceva by Roche and OSI, and Iressa by AstraZeneca) had shown unpredictable effectiveness until it was learned that certain histology subtypes and genetic mutations play a big role in whether the drugs work or the tumors are susceptible to treatment.
Making the treatment algorithms more complicated is the new concept of “maintenance therapy”. Eli Lilly’s drug Alimta (pemetrexed) was recently approved by the FDA for this indication.
To help clarify the state-of-the-art optimal treatment for NSCLC, the new Director of Medical Oncology at The Ohio State University Comprehensive Cancer Center, Miguel A. Villalona-Calero, MD, discusses these topics in depth.
Ohio State University, Oncology | apples49 | 
August 22, 2011 3:08 pm
No Comments
No comments yet.
Notice: comments_rss_link is deprecated since version 2.5! Use post_comments_feed_link() instead. in /data/30/1/121/80/1121895/user/1185656/htdocs/wordpress/wp-includes/functions.php on line 3406
RSS feed for comments on this post.
TrackBack URI
